Ensereptide (PXL01) is a polypeptide derived from human lactoferrin. PXL01 has several mechanisms of action; including immunomodulation and enhancement of fibrinolytic activity. PXL01 produces its immunomodulatory action by inhibiting the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- α (tumor necrosis factor alpha). PXL01 also inhibits the local production of PAI-1 which is an important mediator of fibrinolysis. The anti-inflammatory properties combined with the modulation of fibrinolysis are assumed to account for the ability of the product candidate to prevent post-surgical adhesions and scar formation. Ensereptide (PXL01) is being developed by ProMore Pharma for the treatment of post-surgical adhesions and for prevention of dermal scarring after surgery or trauma.
Originator
Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 09:09:02 UTC 2023
by
admin
on
Sat Dec 16 09:09:02 UTC 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
SMV73KW49C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C169952
Created by
admin on Sat Dec 16 09:09:02 UTC 2023 , Edited by admin on Sat Dec 16 09:09:02 UTC 2023
|
PRIMARY | |||
|
SMV73KW49C
Created by
admin on Sat Dec 16 09:09:02 UTC 2023 , Edited by admin on Sat Dec 16 09:09:02 UTC 2023
|
PRIMARY | |||
|
49863418
Created by
admin on Sat Dec 16 09:09:02 UTC 2023 , Edited by admin on Sat Dec 16 09:09:02 UTC 2023
|
PRIMARY | |||
|
254433-51-7
Created by
admin on Sat Dec 16 09:09:02 UTC 2023 , Edited by admin on Sat Dec 16 09:09:02 UTC 2023
|
PRIMARY | |||
|
9579
Created by
admin on Sat Dec 16 09:09:02 UTC 2023 , Edited by admin on Sat Dec 16 09:09:02 UTC 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_5 | 1_22 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->INHIBITOR OF EXPRESSION |
|
||
|
TARGET->INHIBITOR OF EXPRESSION |
|
||
|
TARGET->ACTIVATOR OF EXPRESSION |
Increased expression of PRG4 mRNA in tendons treated with rabPXL01 in HA, but not in tendon sheaths. In addition, treatment with rabPXL01 in HA led to repression of the mRNA levels for the pro-inflammatory mediators interleukin (IL)-1β, IL-6, and IL-8 in tendon sheaths.
|
||
|
|
TARGET->INHIBITOR OF EXPRESSION |
Increased expression of PRG4 mRNA in tendons treated with rabPXL01 in HA, but not in tendon sheaths. In addition, treatment with rabPXL01 in HA led to repression of the mRNA levels for the pro-inflammatory mediators interleukin (IL)-1β, IL-6, and IL-8 in tendon sheaths.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|